Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 8.2: Therapie der AML mit neuen Substanzen

Autor/en: U. Krug, H. Serve, C. Müller-Tidow, W.E. Berdel
Letzte Änderung: 01.07.2008
  • Alvarado Y et al.
    Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML).
    J Clin Oncol 2007;25:374.


  • Arguello F et al.
    Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts.
    Blood 1998;91:2482-2490.


  • Baer MR et al.
    Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
    Blood 2002;100:1224-1232.


  • Bortul R et al.
    Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
    Br J Haematol 2005;129:677-686.


  • Cairoli R et al.
    Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
    Leuk Res 2005;29:397-400.


  • Cammenga J et al.
    Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.
    Blood 2005;106:3958-3961.


  • Campos L et al.
    High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
    Blood 1993;81:3091-3096.


  • Care RS et al.
    Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.
    Br J Haematol 2003;121:775-777.


  • Carter BZ et al.
    Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells.
    Cell Cycle 2003;2:488-493.


  • Carter BZ et al.
    Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.
    Blood 2005;105:4043-4050.


  • Claus R, Almstedt M, Lubbert M.
    Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Semin Oncol 2005;32:511-520.


  • Cortes J et al.
    A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cancer 2003;97:1234-1241.


  • Cortes J et al.
    Phase I study of bortezomib in refractory or relapsed acute leukemias.
    Clin Cancer Res 2004;10:3371-3376.


  • Craddock C et al.
    Predictors of Clinical Response in Patients with High Risk Acute Myeloid Leukemia Receiving Treatment with the Histone Deacetylase Inhibitor Sodium Valproate.
    Blood 2005;106:783a.


  • Cripe LD et al.
    A Randomized, Placebo-Controlled, Double Blind Trial of the MDR Modulator, Zosuquidar, during Conventional Induction and Post-Remission Therapy for Pts >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS): ECOG 3999.
    Blood 2006;108:164A.


  • D'Amato RJ et al.
    Thalidomide is an inhibitor of angiogenesis.
    Proc Natl Acad Sci USA 1994;91:4082-4085.


  • Dai Y et al.
    Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
    Blood 2005;105:1706-1716.


  • Dias S et al.
    Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.
    J Clin Invest 2000;106:511-521.


  • Fabre C et al.
    Treatment of AML with Azacytidine (AZA): Current results of the French ATU Program.
    Blood 2007;110:1849a.


  • Farmer JA, Torre-Amione G.
    Comparative tolerability of the HMG-CoA reductase inhibitors.
    Drug Saf 2000;23:197-213.


  • Fiedler W et al.
    A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
    Blood 2003;102:2763-2767.


  • Fiedler W et al.
    A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
    Blood 2005;105:986-993.


  • Fiedler W et al.
    An open, phase 1 study of Cediranib in Patients with Acute Myeloid Leukemia (AML).
    Blood 2007;110:895a.


  • Garcia-Manero G et al.
    Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).
    J Clin Oncol 2006a;26:337.


  • Garcia-Manero G et al.
    Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
    Blood 2006b;108:3271-3279.


  • Garcia-Manero G et al.
    Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacytidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
    J Clin Oncol 2007;25:372.


  • Gore SD et al.
    Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacytidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.
    Blood 2006;108:156a.


  • Gottlicher M et al.
    Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.
    Embo J 2001;20:6969-6978.


  • Grandage VL et al.
    PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways.
    Leukemia 2005;19:586-594.


  • Greenberg PL et al.
    Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    J Clin Oncol 2004;22:1078-1086.


  • Harousseau J-L et al.
    A randomised phase 3 study of Tipifarnib compared to best supportive care (including Hydroxyurea) in the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in patients 70 years and older.
    Blood 2007;110:439a.


  • Hidalgo M, Rowinsky EK.
    The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Oncogene 2000;19:6680-6686.


  • Hu J et al.
    Arsenic in cancer therapy.
    Anticancer Drugs 2005;16:119-127.


  • Hubeek I et al.
    Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
    Br J Haematol 2005;131:219-222.


  • Jentsch-Ullrich K et al.
    Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
    Haematologica 2004;89:ECR15.


  • Kadia TM et al.
    A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia.
    J Clin Oncol 2007;25:373.


  • Kaminskas E et al.
    FDA drug approval summary: azacytidine (5-azacytidine, Vidaza) for injectable suspension.
    Oncologist 2005;10:176-182.


  • Kantarjian H et al.
    Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
    Blood 2003;102:2379-2386.


  • Karp JE et al.
    Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Blood 2001;97:3361-3369.


  • Kim R et al.
    Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Cancer 2004;101:2491-2502.


  • Kindler T et al.
    Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
    Blood 2003;101:2960-2962.


  • Kindler T et al.
    Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
    Blood 2004;103:3644-3654.


  • Kizaki M et al.
    Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro.
    Blood 1996;87:1977-1984.


  • Lee EJ et al.
    Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia.
    Leukemia 1990;4:835-838.


  • Levis M et al.
    A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
    Blood 2002;99:3885-3891.


  • Levis M et al.
    A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.
    Blood 2005;106:121a.


  • Lickliter JD et al.
    HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.
    Leukemia 2003;17:2074-2080.


  • Liu XM et al.
    Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo.
    Biochem Pharmacol 1996;51:1545-1551.


  • Lübbert M et al.
    Continued low-dose decitabine (DAC) is an active first-line treatment in ALL cytogenetic subgroups of older AML patients: Results of the FR00331 multicenter phase II study.
    Blood 2007;110:300a.


  • Marcucci G et al.
    A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old.
    J Clin Oncol 2007;25:360.


  • Masuda Y et al.
    Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
    Oncogene 2003;22:1012-1023.


  • Mesa RA et al.
    Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
    Blood 2005;106:318-327.


  • Mesters RM et al.
    Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
    Blood 2001;98:241-243.


  • Minucci S et al.
    Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
    Oncogene 2001;20:3110-3115.


  • Mizuki M et al.
    Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Blood 2000;96:3907-3914.


  • Morgan MA et al.
    Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Leukemia 2003;17:1508-1520.


  • Newman A et al.
    Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin.
    Leukemia 1994;8:2023-2029.


  • Niu C et al.
    Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Blood 1999;94:3315-3324.


  • O'Farrell AM et al.
    SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    Blood 2003;101:3597-3605.


  • O'Reilly MS et al.
    Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
    Cell 1997;88:277-285.


  • Orlowski RZ et al.
    Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
    Blood 2005;105:3058-3065.


  • Padro T et al.
    Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
    Blood 2000;95:2637-2644.


  • Padro T et al.
    Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
    Leukemia 2002;16:1302-1310.


  • Pearce D et al.
    The Specific Aurora Kinase Inhibitor AZD1152 Significantly Affects the Growth of Human Leukaemic Cells in an In Vivo AML Model.
    Blood 2006;108:52a.


  • Petti MC et al.
    Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
    Leukemia 1993;7(Suppl1):36-41.


  • Pirker R et al.
    MDR1 gene expression and treatment outcome in acute myeloid leukemia.
    J Natl Cancer Inst 1991;83:708-712.


  • Prendergast GC.
    Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
    Curr Opin Cell Biol 2000;12:166-173.


  • Quintas-Cardama A et al.
    Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML).
    J Clin Oncol 2007;25:361.


  • Recher C et al.
    Antileukemic activity of rapamycin in acute myeloid leukemia.
    Blood 2005;105:2527-2534.


  • Reiter A.
    Identification of molecular targets and treatments options in myeloproliferative disorders.
    Präsentation auf dem EHA-Kongress, Satellitensymposium, Wien, 2007.


  • Reuter CW, Morgan MA, Bergmann L.
    Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
    Blood 2000;96:1655-1669.


  • Robertson KD.
    DNA methylation and human disease.
    Nat Rev Genet 2005;6:597-610.


  • Robin M et al.
    Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
    Cancer Immunol Immunother 2005;54:933-943.


  • Rosato RR et al.
    Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Mol Cancer Ther 2005;4:1772-1785.


  • Schimmer AD et al.
    Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy.
    Cancer Res 2003;63:1242-1248.


  • Schittenhelm M et al.
    Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).
    Leuk Lymphoma 2003;44:1251-1253.


  • Schmelzle T, Hall MN.
    TOR, a central controller of cell growth.
    Cell 2000;103:253-262.


  • Schwartsmann G et al.
    Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
    Leukemia 1997;11(Suppl1):28-31.


  • Silverman LR et al.
    Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
    J Clin Oncol 2002;20:2429-2440.


  • Simon M et al.
    Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia.
    Oncogene 2005;24:2410-2420.


  • Singhal S et al.
    Antitumor activity of thalidomide in refractory multiple myeloma.
    N Engl J Med 1999;341:1565-1571.


  • Smith BD et al.
    Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
    Blood 2004;103:3669-3676.


  • Soligo D et al.
    The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.
    Br J Haematol 2001;113:126-135.


  • Soriano AO et al.
    Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study.
    Blood 2006;108:51a.


  • Spiekermann K et al.
    Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
    Exp Hematol 2002;30:262-271.


  • Stegmaier K et al.
    Gefitinib induces myeloid differentiation of acute myeloid leukemia.
    Blood 2005;106:2841-2848.


  • Steins MB et al.
    Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
    Blood 2002;99:834-839.


  • Stone RM et al.
    Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.
    Blood 2005a;106:121a.


  • Stone RM et al.
    Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
    Blood 2005b;105:54-60.


  • Sujobert P et al.
    Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
    Blood 2005;106:1063-1066.


  • Suzuki K et al.
    Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells.
    Br J Haematol 2005;130:681-690.


  • Tamburini J et al.
    Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years.
    Blood 2006;108:537a.


  • Thomas DA et al.
    Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol 2003;123:436-441.


  • Towatari M et al.
    Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells.
    Leukemia 1997;11:479-484.


  • Tsai DE et al.
    A phase I trial of bexarotene, a retinoid X receptor agonist, in non-M3 acute myeloid leukemia.
    J Clin Oncol 2007;25:372.


  • van der Holt B et al.
    The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
    Blood 2005;106:2646-2654.


  • Viniou NA et al.
    Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
    Eur J Haematol 2004;72:58-60.


  • Wang G et al.
    An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Hematol Oncol 2004;22:63-71.


  • Weisberg E et al.
    Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
    Cancer Cell 2002;1:433-443.


  • Wijermans PW et al.
    An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
    Ann Hematol 2005;84 (Suppl 13):9-17.


  • Willemze R et al.
    A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
    Leukemia 1997;11(Suppl1):24-27.


  • Wu J et al.
    Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
    Cancer Res 2004;64:6461-6468.


  • Xia Z et al.
    Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.
    Leukemia 2001;15:1398-1407.


  • Yamamoto Y et al.
    Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
    Blood 2001;97:2434-2439.


  • Yokota S et al.
    Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.
    Leukemia 1997;11:1605-1609.


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag" (Publikation als Buch)
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
und in Kooperation mit "Studien-Allianz Leukämie"
Deutscher Ärzte-Verlag  Studien-Allianz Leukämien
[Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]